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Abstract: Somatostatin analogs (SSA) are widely used to treat conditions associated with
hormonal hypersecretion such as acromegaly and metastatic neuroendocrine tumors.
First generation SSA, such as, octreotide and lanreotide have high affinity for
somatostatin receptor (SSTR) subtype 2 (SSTR2), but have incomplete efficacy in
many patients.  Pasireotide targets multiple SSTRs, having the highest affinity for
SSTR5, but causes hyperglycemia and diabetes mellitus in preclinical and clinical
studies.  AP102 is a new SSA with high affinity at both SSTR2 and SSTR5.  We aimed
to characterize the effects of AP102 versus pasireotide on random and dynamic
glucose levels, glucoregulatory hormone concentrations and growth axis measures in
healthy Sprague-Dawley rats. Three doses of each compound were evaluated under
acute conditions (1, 10 and 30 µg/kg s.c.), and two doses during a chronic (4-week)
infusion (3 and 10 µg/kg/h s.c.). Neither acute nor chronic AP102 administration altered
blood glucose concentrations or dynamic responses following an intraperitoneal
glucose tolerance test (ipGTT).  In contrast, acute and chronic pasireotide dosing
increased random and post-ipGTT blood glucose measures, compared to vehicle-
treated controls.  Both AP102 and pasireotide acutely suppressed growth hormone
(GH) levels, although insulin-like growth factor-1 (IGF-1) and somatic growth was
suppressed to a greater extent with pasireotide. AP102 is a new dual SSTR2/SSTR5-
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Abstract 29 
Somatostatin analogs (SSA) are widely used to treat conditions associated with hormonal 30 
hypersecretion such as acromegaly and metastatic neuroendocrine tumors.  First generation SSA, such 31 
as, octreotide and lanreotide have high affinity for somatostatin receptor (SSTR) subtype 2 (SSTR2), 32 
but have incomplete efficacy in many patients.  Pasireotide targets multiple SSTRs, having the highest 33 
affinity for SSTR5, but causes hyperglycemia and diabetes mellitus in preclinical and clinical studies.  34 
AP102 is a new SSA with high affinity at both SSTR2 and SSTR5.  We aimed to characterize the 35 
effects of AP102 versus pasireotide on random and dynamic glucose levels, glucoregulatory hormone 36 
concentrations and growth axis measures in healthy Sprague-Dawley rats. Three doses of each 37 
compound were evaluated under acute conditions (1, 10 and 30 µg/kg s.c.), and two doses during a 38 
chronic (4-week) infusion (3 and 10 µg/kg/h s.c.). Neither acute nor chronic AP102 administration 39 
altered blood glucose concentrations or dynamic responses following an intraperitoneal glucose 40 
tolerance test (ipGTT).  In contrast, acute and chronic pasireotide dosing increased random and post-41 
ipGTT blood glucose measures, compared to vehicle-treated controls.  Both AP102 and pasireotide 42 
acutely suppressed growth hormone (GH) levels, although insulin-like growth factor-1 (IGF-1) and 43 
somatic growth was suppressed to a greater extent with pasireotide. AP102 is a new dual 44 
SSTR2/SSTR5-specific SSA that acutely reduces GH but does not cause hyperglycemia during acute 45 
or chronic administration in a healthy rat model.  Further studies in diabetic animals and in humans 46 
are necessary to determine the potential utility of AP102 in the clinical setting. 47 
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 3 
Introduction 49 
Acromegaly is a rare, chronic disorder characterized by excess secretion of growth hormone (GH) and 50 
insulin-like growth factor 1 (IGF-1), usually due to a somatotrope cell tumor of the pituitary gland [1]. 51 
The main medical treatment option is administration of somatostatin analogs (SSAs; also known as 52 
somatostatin receptor ligands), which inhibit GH and IGF-1 secretion and can shrink pituitary tumor 53 
size [2].  SSAs are also used in the treatment of metastatic neuroendocrine tumors (NET) in order to 54 
control signs and symptoms associated with tumoral secretion of neurotransmitters and hormones.  55 
The established SSAs, octreotide and lanreotide, mediate their actions via somatostatin receptor 56 
subtype 2 (SSTR2).  However, these SSTR2-specific compounds have incomplete efficacy in the 57 
clinical management of acromegaly and often patients do not achieve the high levels of strict 58 
hormonal control reported in randomized clinical trials [3,4].  The newer SSA, pasireotide, has high 59 
affinity for multiple SSTRs, particularly SSTR5 and is approved for the treatment of Cushing’s 60 
disease (via SSTR5-mediated ACTH inhibition), in addition to acromegaly [5-7].  Apart from the 61 
wider SSTR binding profile, the interactions of pasireotide with SSTR2 differs from that of octreotide 62 
due to specific patterns of phosphorylation and internalization [8-10]. Expanding the SSTR binding 63 
profile for SSA beyond SSTR2 alone has clinical benefit.  For instance, in acromegaly patients that 64 
were insufficiently controlled with octreotide, switching to pasireotide led to improved GH and IGF-1 65 
control in 17.3% of cases [11]. However, the SSTR binding and interaction profile of pasireotide also 66 
leads to undesirable effects on glucose metabolism that are not seen with SSTR2-specific compounds.   67 
In the rat, chronic administration of pasireotide but not octreotide led to increased glucose levels; this 68 
was associated with decreased insulin in both groups as compared with controls, while octreotide also 69 
blunted glucagon secretion [12]. Following a glucose tolerance test (GTT) in healthy human 70 
volunteers, pasireotide treatment decreased insulin and incretin responses, leading to increased 71 
glycemia; this effect could be ameliorated with concomitant use of certain anti-diabetic medications 72 
[13,14].  In clinical trials of pasireotide examining both the subcutaneous and long acting repeatable 73 
(LAR) formulations, adverse events and discontinuations attributable to hyperglycaemia and diabetes 74 
mellitus occurred with greater frequency than in patients treated with octreotide/lanreotide [6,7,11,15-75 
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 4 
17].  Use of pasireotide in acromegaly and Cushing’s disease requires specific vigilance to recognize 76 
hyperglycemia and to treat new onset diabetes mellitus using anti-diabetic medication [18-20]. 77 
Given the incomplete clinical control achieved with established SSA and the issues relating to glucose 78 
metabolism with pasireotide, interest remains in new SSAs with a different profile of SSTR binding 79 
than existing compounds.  AP102 is a disulfide-bridged octapeptide SSA containing synthetic 80 
iodinated amino acids (Compound 9 in [21]). Receptor binding studies have previously demonstrated 81 
that AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50 : 0.63 and 0.65 nM, 82 
respectively), which were similar to the affinities obtained for native somatostatin 14 in the same 83 
experiments (IC50 : 0.4 and 0.2 nM, respectively) [21].  Further, AP102 does not bind to SSTR1 or 84 
SSTR3, which is in stark contrast to pasireotide [21,22]. AP102 also inhibited GHRH-stimulated GH 85 
release and prolactin release from rat anterior pituitary cells in vitro [21]. The IC50 levels for GH and 86 
prolactin inhibition were low (0.15 and 0.23 nM, respectively) and were similar to those obtained with 87 
somatostatin 14 (0.1 and 0.2 nM, respectively).  Given this profile of high SSTR2 and SSTR5 affinity 88 
and GH/prolactin inhibition in vitro, AP102 might represent an interesting candidate for use in the 89 
clinical treatment of acromegaly or NET. 90 
The aim of this study was to characterize the effects of AP102 on in vivo hormonal secretion and 91 
glucose metabolism following acute (single dose) and chronic (28-day) administration in Sprague 92 
Dawley rats and to compare the profile of AP102 with that of pasireotide at identical dose levels.    93 
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Methods 94 
Animals 95 
All experiments were performed with male Sprague Dawley rats (Janvier Labs, Le Genest-St-Isle, 96 
France). Rats were approximately 5 weeks old on arrival at the study center, which corresponds to a 97 
period of rapid somatic growth in young animals.  The experiments were approved by the Kantonales 98 
Veterinäramt Zurich, Switzerland. Upon arrival at the facility, rats were given at least one week to 99 
acclimate to the new environmental and housing conditions.  100 
 101 
Compounds 102 
AP102 was synthesized as acetate salt by Polypeptide (San Diego, CA, USA). Commercially 103 
available pasireotide (Signifor; Novartis Pharma Schweiz) was used. AP102 and pasireotide were 104 
reconstituted and diluted in sterile 0.9% NaCl, which was also used as vehicle control, and 500-μl 105 
aliquots of 0.03 μg/ml were stored at -20 °C until use. On the day of testing, aliquots were diluted 106 
with sterile saline to the appropriate concentration, and kept on ice until used. 107 
 108 
Single-dose subcutaneous administration study 109 
56 male Sprague Dawley rats (150 g at arrival, approx. 5 weeks in age) were group housed (3 to 4 rats 110 
per cage; Tecniplast cage type IV S; 48 x 38 x 21 cm) under a 12/12-h light-dark cycle (lights on at 111 
07.00 h) in a temperature-controlled environment, with ad libitum access to standard chow (D3430; 112 
Provimi-Kliba, Kaiseraugst, Switzerland) and water. Rats of this age are in an active growth phase; 113 
therefore body weight was measured daily throughout the experiment. 114 
When weighing approximately 300 g, rats received chronic catheters into the carotid artery fitted to a 115 
vascular access button (VAB95BS; Instech Laboratories, Inc) exteriorized between the scapulae and 116 
covered with a protective cap to facilitate group housing. Rats were initially sedated with 4-5% 117 
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 6 
isoflurane (O2 flow rate at 0.8 l/min), and maintained at 2-3% isoflurane for the remainder of the 118 
surgery. Rats were treated postoperatively with fluids (5 ml sterile Ringer-Lactate SC), antibiotics 119 
(Enrofloxacin; 5.7 mg/kg SC), and analgesics (Flunixin; 1 mg/kg SC). Following catheter 120 
implantation, infusion lines were filled with a lock solution (100 U/ml heparin in 50% glycerol), and 121 
were not manipulated until the day of testing, unless there was blood visible in the line. 122 
One week after catheterization, rats with patent catheters (75 % of operated rats) were assigned 123 
randomly across home cages to treatment groups and injected with AP102 (1, 10, and 30 µg/kg), 124 
pasireotide (1, 10, and 30 µg/kg), or vehicle subcutaneously (n=6 analyzed for each group), beginning 125 
90 min after light onset (08:30h). Blood samples (300 μl) were withdrawn from the carotid catheter 126 
before treatment (~08:00h), and at 0.25, 0.5, 1, 3, and 6 h post-administration. Blood glucose was 127 
measured directly from whole blood using a Nova StatStrip glucometer (DSI; St. Paul MN, USA). 128 
The remaining blood sample was collected in Na-EDTA-coated tubes containing a general protease 129 
inhibitor cocktail (P2714; Sigma; 30 μl of 1:10 diluted stock solution/1 ml blood) and a DPP-4 130 
inhibitor (DPP-4-010; Millipore; 10 μl/1 ml blood). Samples were kept at 4 °C until spun for 10 min 131 
at 1000 x g (4 °C), and then plasma was immediately aliquoted into separate tubes and stored at -80 132 
°C until assayed for insulin, glucagon and GLP-1 in duplicate (K15159C-1; Mesoscale Mouse/Rat 133 
GLP-1 (7-36) amide, Insulin, Glucagon custom kit), and GH in triplicate (EZRMGH-45K; Merck-134 
Millipore Rat/Mouse Growth Hormone ELISA Kit). 135 
 136 
Chronic 28- day continuous subcutaneous infusion study 137 
Animals: 44 male Sprague Dawley rats (180 g at arrival) were group housed as described before. 138 
Body weight was measured at least three times per week. On day 0, under isoflurane anesthesia and 139 
prior to minipump implantation, the nose-to-anus and the tail length were measured. Body length 140 
measurements were taken again on days 14 and 28. Femur length was also recorded at necropsy on 141 
day 28. 142 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 7 
Mini-pump Preparation and Implantation: Mini-pumps for sub-cutaneous administration (Alzet model 143 
2ML2) were filled with the AP102, pasireotide or vehicle one day prior to implantation, and then left 144 
to equilibrate at 37 °C in sterile saline so that pumps were primed when implanted. The first day of 145 
implantation was designated as day 0. Under sterile conditions, a small incision was made between 146 
the scapulae and the mini-pump was subcutaneously implanted. Rats were initially sedated with 4-5% 147 
isoflurane (O2 flow rate at 0.8 l/min), and maintained at 2-3% isoflurane for the remainder of the 148 
surgery. Immediately following surgery and 1 day post-op (after the day 1 blood sample), rats 149 
received SC injection of 5 ml Ringer-Lactate, antibiotics (Enrofloxacin; 5.7 mg/kg SC injected into a 150 
subcutaneous NaCl depot), and analgesics (Flunixin; 1 mg/kg SC). After 2 weeks of infusion, the 151 
minipumps were removed under isoflurane anesthesia, and replaced with a second 2ML2 minipump 152 
containing the same infusate for the second 2-week period. Treatment and groups were as follows: 153 
vehicle (n=8); AP102 3 µg/kg/h (n=9); AP102 10 µg/kg/h (n=9); pasireotide 3 µg/kg/h (n=8); 154 
pasireotide 10 µg/kg/h (n=8). Rats were semi-randomly assigned to treatment groups, ensuring no 155 
difference in day 0 body weight across groups. Acute and chronic doses where chosen based on 156 
previously published studies investigating the effects of pasireotide on glucose homeostasis in rats 157 
[12].  158 
Blood samples (500 μl) were collected from the sublingual vein immediately before mini-pump 159 
implantation on day 0, and on days 1, 7, 14, and 21 after the start of treatment. Blood samples were 160 
collected between 10 :00 and 12 :00 each day, with the exception of the Day 0 sample, which was 161 
collected immediately before minipump implantation (08:00). Immediately after being briefly 162 
anesthetized by inhalation of 5% isoflurane, a sublingual vein was punctured with a 20 G needle, and 163 
blood was collected in Na-EDTA-coated tubes containing protease inhibitors, as described above. 164 
Samples were kept at 4 °C until spun for 10 min at 1000 x g (4 °C), and then plasma was immediately 165 
aliquoted into separate tubes and stored at -80 °C until assayed. On day 28, rats were deeply 166 
anesthetized with isoflurane, the heart was exposed, and a terminal blood sample of 2 to 3 ml was 167 
collected via heart puncture, and plasma was extracted and stored as above. Glucose, insulin, 168 
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 8 
glucagon and GLP-1 were measured as before. IGF-1 was measured in triplicate using the Rat/Mouse 169 
IGF-1 ELISA kit (AC-18F1; Immunodiagnostics Systems Ltd). 170 
On day 21 of treatment, rats were briefly anesthetized by inhalation of 5% isoflurane, placed in a 171 
supine position and the tongue extended from the mouth using a cotton-tipped applicator. One of the 172 
sublingual veins was punctured with a 20 G needle, and 500 μl blood was collected in Na-EDTA-173 
coated tubes and treated with inhibitors, as described above. This sample was used for day 21 baseline 174 
analyses and for pre-glucose comparison; Blood glucose was measured directly from whole blood 175 
using Nova StatStrip glucometer (Data Sciences International). Before recovery from isoflurane, rats 176 
were injected i.p. with 1.5 g/kg glucose (50% glucose solution). Rats were then allowed to recover 177 
from anesthesia. Thirty minutes later, rats were again anesthetized and a second sublingual blood 178 
sample of 300 μl was collected as described above. A full glucose tolerance test time-course was not 179 
performed due to limitations in the volume of blood safely collected from the rats. Only rats 180 
demonstrating a rise in blood glucose above 200 mg/dL 15 min after glucose injection were included 181 
in the analysis. Resulting group sizes were: Vehicle (n=4); AP102 3 µg/kg/h (n=6); AP102 10 µg/kg/h 182 
(n=6); pasireotide 3 µg/kg/h (n=6); pasireotide 10 µg/kg/h (n=6).   183 
 184 
Determination of AP102 stability in the experimental conditions 185 
Three mini-pumps were prepared under identical conditions as described above, but were not 186 
implanted in rats. AP102 solutions at 0.19 and 0.64 mg/mL (equivalent to 3 µg/kg/h and 10 µg/kg/h 187 
AP102 infusate solutions) or saline were placed in the mini-pumps, infused during 13 days at 37°C 188 
and collected in Eppendorf tubes every day. The peptide content was quantified by liquid 189 
chromatography–mass spectrometry (LC-MS/MS) in these samples, in residual solution from the 190 
mini-pumps, and in stock and working solutions described in acute and chronic experiments to assess 191 
its stability and the absence of adsorption on surfaces. All samples were 60-fold diluted in saline 192 
before analysis. 193 
 194 
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 9 
Statistical Analysis 195 
Statistical analysis was done using Prism 7 (Graph Pad Software, La Jolla, CA, USA). One-way and 196 
two-way repeated measures ANOVA analyses were followed by Bonferroni adjustment for multiple 197 
comparisons, when appropriate. Total area under the curve (AUC) was calculated using the 198 
trapezoidal rule.  A P-value of < 0.05 was considered statistically significant for all experiments.  199 
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Results 200 
The acute study was performed to determine the effect of single doses of AP102 and pasireotide on 201 
blood glucose and GH levels. Six hours after acute treatment, we observed significant reductions in 202 
circulating GH in rats treated with pasireotide (10 and 30 μg/kg doses [p < 0.001 for both]) and 203 
AP102 (1 μg/kg [p < 0.05] and 30 μg/kg doses [p < 0.001]), as compared to vehicle-treated rats 204 
(Figure 1A). The corresponding AUC analysis revealed that 10 and 30 μg/kg pasireotide  (p < 0.01 for 205 
both) and 30 μg/kg AP102 (p < 0.05) suppressed GH levels compared to vehicle (Figure 1A inset).  206 
Acute administration of AP102 had no effect on glucose levels (Figure 1B).  Pasireotide treatment led 207 
to increased plasma glucose in all three dose-groups during the first hour and remained significantly 208 
elevated in the highest dose group at 6 hours.  We were unable to detect differences in plasma insulin, 209 
glucagon, or GLP-1 following acute administration of AP102 and pasireotide due to high variability 210 
in the samples (data not shown). We suspect the high variability resulted from not fasting the rats 211 
prior to the acute injection; thus we could not control for the time since the last meal, which can affect 212 
the levels of these metabolic hormones.  213 
Chronic AP102 treatment transiently decreased blood glucose levels as compared to vehicle (Figure 214 
2A). The effect was significant on the first day of infusion in both the 3 μg/kg/h (p<0.05) and 10 215 
μg/kg/h (p<0.001) groups.  This remained significant in the 10 μg/kg/h group until day 7 of infusion 216 
(p<0.01); AUC showed that both AP102 doses lowered glucose levels compared to vehicle (p<0.001 217 
for both; Figure 2A inset). Pasireotide led to an initial, non-significant rise in plasma glucose, and 218 
glucose levels remained at or above those of vehicle for the whole study duration.  Insulin levels were 219 
suppressed in both AP102 and pasireotide treated groups as compared with vehicle treated (Figure 2B 220 
AUC inset; p<0.001 for all group). These differences did not reach statistical significance at 221 
individual time points, likely due to large variability in the control group.  Similarly, glucagon levels 222 
were similar in all study groups up to day 21, but were significantly lower in the AP102 treated 223 
groups (p<0.01 for both) than in the vehicle or pasireotide treated groups on day 28 (Figure 2C).  224 
GLP-1 levels decreased in the pasireotide treated groups immediately after infusion began, being 225 
significantly decreased versus vehicle in the 3 μg/kg/h pasireotide group on Day 1 (Figure 2D).  226 
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Thereafter GLP-1 levels remained numerically lower than vehicle throughout the study and lower 227 
overall according to AUC (p<0.001 for both; Figure 2D inset), whereas in AP102 treated rats GLP-1 228 
levels were generally at or above those seen with vehicle and pasireotide. 229 
On day 21 of the chronic treatment period, rats underwent an ipGTT.  AP102 had no impact on 230 
plasma glucose levels following ipGTT.  Glucose was significantly increased as compared to vehicle 231 
in the 3 μg/kg/h pasireotide group at 60 min (p < 0.05; Figure 3A).  The rise in insulin 30 minutes 232 
after glucose administration was significantly lower in the pasireotide-treated groups than vehicle 233 
treated controls (p<0.01; Figure 3B and inset).  AP102 did not differ significantly from vehicle in 234 
terms of insulin levels post ipGTT (Figure 3B), though AUC was significantly lower in the 3 μg/kg/h 235 
AP102 group compared to vehicle (p<0.05; Figure 3B inset).  During the ipGTT, glucagon levels in 236 
the AP102 groups remained below the lower limit of detection at 30 minutes, whereas pasireotide 237 
groups demonstrated numerically higher glucagon levels than controls (Figure 3C).  At baseline 238 
before the ipGTT, AP102 treated groups had numerically higher GLP-1 levels, which remained higher 239 
than vehicle and pasireotide groups at the 30 minute time point (Figure 3D), but did not reach 240 
statistical significance. 241 
Chronic infusion of AP102 significantly reduced IGF-1 on the first full day after the start of the 242 
infusion (P<0.001 in both dose groups); thereafter IGF-1 remained 15-20% lower than the vehicle 243 
group through to the end of the study; though not statistically significant at individual time points, 244 
AUC was significantly lower in both the 3 μg/kg/h (p < 0.01) and 10 μg/kg/h (p < 0.001) AP102 245 
groups compared to vehicle (Figure 4). Both doses of pasireotide suppressed IGF-1 compared with 246 
vehicle across the 28-day period (p < 0.001), and evident from the AUC analysis (p < 0.001).  Rats 247 
treated with both doses of pasireotide and the 10 μg/kg/h dose of AP102 gained significantly less 248 
body weight than vehicle-treated controls (p-values provided in Figure 5A). In the pasireotide groups, 249 
decreased body length (p < 0.001 for both doses on days 14 and 28), tail length (p < 0.001 for 10 250 
μg/kg/h group on both days; p < 0.05 on day 14 and p < 0.01 on day 28 for 3 μg/kg/h group), and 251 
femur length (p < 0.001 for both doses on day 28) were seen.  With AP102 treatment, only tail length 252 
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was decreased by the higher dose at the end of the study (day 28 in the 10 μg/kg/h group; Figures 5B-253 
5D).  254 
LC-MS/MS analyses showed that the stock and working solutions, the residual solution in the mini-255 
pumps after 13 days and the samples collected from the mini-pumps after one and 13 days contained 256 
the expected amounts of peptide. These results show that AP102 was stable in the mini-pumps 257 
delivering the peptide to the rats for 13 days at 37°C. Moreover, AP102 was neither adsorbed on the 258 
surface of the mini-pumps nor on the containers used for the preparation of stock and working 259 
solutions (data not shown). 260 
  261 
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Discussion 262 
This study aimed to characterize the effects of acute and chronic treatment of a new dual 263 
SSTR2/SSTR5 specific SSA, AP102 on glucose metabolism, hormonal measures, and growth in 264 
healthy growing rats.  Following acute and chronic administration, in vivo AP102 did not lead to 265 
hyperglycemia or impaired glucose tolerance in this model.  These data indicate that a low or sub-266 
nanomolar binding affinity at SSTR2 and SSTR5 is not necessarily associated with an increased risk 267 
of hyperglycemia.  268 
Our acute study clearly showed that AP102 does not induce hyperglycemia in rats, which contrasts 269 
the well-documented hyperglycemic effect of pasireotide in rats and humans [12,13] that we also 270 
reproduced here. The high variability in the concentrations of glucoregulatory hormones that we 271 
observed in the acute study did not allow us to draw conclusions about the underlying mechanisms 272 
following a single treatment. The results of the chronic study, however, provide additional insight, 273 
suggesting that AP102 likely influences glycemia by a more balanced suppression of insulin and 274 
glucagon compared to pasireotide. 275 
In our chronic study, AP102 was also associated with lower glucose concentrations as compared with 276 
vehicle and pasireotide treated groups, while insulin was reduced to a similar degree as with 277 
pasireotide. In an earlier experiment, in which healthy rats were infused with pasireotide at the same 278 
doses we administered for 14 days duration, pasireotide was associated with increased plasma glucose 279 
levels at days 1 and 7 versus a vehicle-treated group [12].  In that study, the comparator was the 280 
SSTR2-specific compound octreotide, which was associated with a tendency to lower blood glucose 281 
during continuous infusion.  While both octreotide and pasireotide reduced plasma insulin 282 
concentrations, octreotide was associated with a concomitant reduction in glucagon that did not occur 283 
with pasireotide. Like octreotide, AP102 lowered glucagon levels, most notably at the end of the 28-284 
day infusion period.  Suppression of glucagon by AP102 appears to offset the inhibitory effect on 285 
insulin, resulting in a net glucose-neutral effect during chronic administration and following the 286 
ipGTT. The results of the ipGTT on day 21 further support the interpretation that chronic AP102 287 
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modifies glucose-stimulated hormone release in different and less diabetogenic manner than 288 
pasireotide.   Specifically, glucagon was completely undetectable in the AP102 groups 30 minutes 289 
after glucose challenge, and only the pasireotide-treated groups had significant blunting of glucose-290 
simulated insulin levels. Findings from the chronic and ipGTT studies also lead us to hypothesize that 291 
GLP-1 plays a secondary role in counteracting hyperglycemia after AP102 treatment. We observed 292 
lower GLP-1 levels in the groups treated chronically with pasireotide, while chronic AP102 treatment 293 
resulted in GLP-1 levels numerically higher than the vehicle-treated group. GLP-1 levels in the 294 
AP102 groups were also numerically higher than the vehicle and pasireotide groups both at the 295 
beginning of the ipGTT and 30 minutes after glucose stimulation. Human data showing that 296 
pasireotide can suppress glucose-stimulated GLP-1 release suggest that the hyperglycemic effects of 297 
pasireotide are explained by a combination of insulin and incretin inhibition [13]. While the incretin 298 
effect of GLP-1, whereby GLP-1 increases insulin secretion, is well established, it is also known that 299 
GLP-1 can enhance insulin activity and improve glucose tolerance independently of modifying insulin 300 
release [23-25]. Thus the increased, or at least non-suppressed, GLP-1 levels following AP102 301 
treatment might help to counter the reduced insulin levels by enhancing insulin action and thereby 302 
contributing to the net lowering of glucose. Taken together these results suggest that AP102 has a 303 
neutral effect on glucose via a balanced inhibition of insulin and glucagon release, and potential 304 
enhancement of insulin action resulting from uninhibited GLP-1 levels.   305 
The other main aim of the study was to assess the effect of AP102 on GH and IGF-1 secretion. Six 306 
hours after a single treatment, the highest dose of AP102 reduced GH levels compared to vehicle-307 
treated rats, and the effect of AP102 was comparable to that produced by the two highest doses of 308 
pasireotide. The high inter-animal variability in GH levels across treatment groups and time points 309 
likely results from the short half-life and pulsatile pattern of release of GH, substantiating claims that 310 
the direct measurement of GH in plasma is challenging and can lack utility when assessing the 311 
efficacy of SSA-based treatments [26]. IGF-1 levels, which provide an indirect readout of GH 312 
activity, were measured in the chronic study to circumvent these limitations. AP102 strongly 313 
suppressed IGF-1 after one day of continuous infusion, and then maintained IGF-1 levels at 15-20% 314 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
of baseline, while pasireotide lowered IGF-1 to approximately 50% of baseline over the 28-day study. 315 
Normal growth was also significantly reduced by pasireotide versus controls in terms of femur length, 316 
body weight, and body and tail length.  Similar to its effect on IGF-1, AP102 led to numerically lower 317 
growth measures than controls, but this was only significant for inhibition of tail length at the end of 318 
the 28-day study.  The effects of AP102 and pasireotide on physiological GH-IGF-1 axis function and 319 
somatic growth clearly differ.  This mirrors what has been established regarding octreotide.  320 
Octreotide has only a transient inhibitory effect on physiological secretion of GH and IGF-1 in the rat.  321 
This was first established by Lamberts et al in 1987, who demonstrated that daily administration of 322 
octreotide in healthy rats initially led to GH inhibition for up to 6 days [27]. Thereafter, the effect of 323 
octreotide was desensitized and at day 15 GH levels were identical in octreotide-treated and control 324 
rats.  Schmid & Brueggen also found a similar desensitization of the chronic effect of octreotide in 325 
healthy rats, which contrasted with the significant inhibition of physiological IGF-1 secretion and 326 
growth with pasireotide [12].  Pasireotide also inhibits GH/IGF-1 secretion in patients with normal 327 
GH axis, as has been shown in Cushing’s disease [28].  These findings highlight a limitation of the 328 
normal rat model in comparing the potential hormonal profile of SSA in the pathological setting of 329 
acromegaly in humans.  Despite the transient effect on hormonal secretion in the rat, octreotide 330 
effectively controls pituitary tumor related GH and IGF-1 hypersecretion in acromegaly during 331 
chronic treatment for years without desensitization occurring.   332 
 333 
The explanation of why AP102 and pasireotide produced very different patterns of effects on glucose 334 
metabolism, despite both having high affinities for SSTR2 and SSTR5, requires further investigation.  335 
There are, however, a number of factors that are likely to play a role in this difference.  Pasireotide 336 
binds with high affinity to other somatostatin receptors apart from SSTR2 and SSTR5, such as SSRT3 337 
and SSTR1, whereas AP102 is limited to SSTR2 and SSTR5 only.  Effects at these other receptors 338 
might play a role in pasireotide-related glucose excursions.  For instance, SSTR3 is highly expressed 339 
in the pancreatic islets of humans and rodents and recently SSTR3 antagonists have been developed 340 
for the treatment of type 2 diabetes [29].  Pasireotide has also been shown to differ significantly from 341 
other somatostatin analogs in terms of its phosphorylation profile at certain SSTRs [9,30]. It is also 342 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
important to note that SSA-binding affinities do not directly predict the functionality at the specific 343 
SSTRs [31]. For example, pasireotide was shown to activate a different pattern of signal transduction 344 
than octreotide upon binding to SSTR2 [32]. The interactions between AP102 and SSTR2 and SSTR5 345 
receptors have not yet been studied in this manner, but could contribute to the differences from 346 
pasireotide in SSTR-driven effects on glucose metabolism that we report. 347 
 348 
In conclusion, administration of AP102 was not associated with impairment of glucose control in a 349 
healthy rat model, which suggests that balanced, high affinity binding to SSTR2 and SSTR5 can be 350 
achieved without diabetogenic effects.  The risk of impaired glucose control in humans with 351 
acromegaly treated with pasireotide is higher in those with elevated pre-treatment blood glucose 352 
levels. Therefore, further comparative studies using AP102 in animal models of type 2 diabetes could 353 
help to clarify the potential utility of AP102 in clinical practice, especially for patients in whom 354 
diabetes is a highly undesirable complication of treatment. 355 
 356 
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Figure Legends 490 
Figure 1: Mean (± SEM) plasma growth hormone (A) and blood glucose (B) levels measured before 491 
and 0.25, 0.5, 1, 3, and 6 hours after SC treatment with vehicle (sterile saline), pasireotide (1, 10, or 492 
30 μg/kg) or AP102 (1, 10, or 30 μg/kg) in male rats. Insets show mean (± SEM) area under the curve 493 
(AUC) for growth hormone (A) and glucose levels (B) over the six-hour test period. Symbols denote 494 
significant differences from vehicle treatment: pasireotide 30 μg/kg: **P≤0.01, ***P≤0.001; 495 
pasireotide 10 μg/kg: +P≤0.05, ++P≤0.01, +++P≤0.001; pasireotide 1 μg/kg: °P≤0.05, °°°P≤0.001; 496 
AP102 30 μg/kg: ^P≤0.05, ^^^P≤0.001; AP102 1 μg/kg: †P≤0.05 497 
 498 
Figure 2: Mean (± SEM) blood glucose (A), plasma insulin (B), plasma glucagon (C), and plasma 499 
GLP-1 (D) levels measured before and following 1, 7, 14, 21, and 28 days of chronic SC treatment 500 
with vehicle (sterile saline), pasireotide (3 or 10 μg/kg/h) or AP102 (3 or 10 μg/kg/h) in male rats. 501 
Insets show mean (± SEM) area under the curve (AUC) for glucose (A), insulin (B), glucagon (C), 502 
and GLP-1 levels (D) during the 28-day treatment period. Symbols denote significant differences 503 
from vehicle treatment: pasireotide 10 μg/kg/h: ***P≤0.001; pasireotide 3 μg/kg/h: +P≤0.05, 504 
++P≤0.01, +++P≤0.001; AP102 10 μg/kg/h: °°P≤0.01; °°°P≤0.001; AP102 3 μg/kg/h: ^P≤0.05, 505 
^^P≤0.01, ^^^P≤0.001 506 
 507 
Figure 3: Mean (± SEM) blood glucose (A) and glucose-stimulated plasma levels of insulin (B), 508 
glucagon (C), and GLP-1 (D) following IP glucose tolerance test in male rats chronically treated for 509 
21 days with vehicle (sterile saline), pasireotide (3 or 10 μg/kg/h) or AP102 (3 or 10 μg/kg/h). Insets 510 
show mean (± SEM) area under the curve (AUC) for glucose (A), insulin (B), glucagon (C), and 511 
GLP-1 levels (D) in response to the glucose challenge. Symbol denotes significant differences from 512 
vehicle treatment at individual time points: pasireotide 10 μg/kg/h: **P≤0.01; pasireotide 3 μg/kg/h: 513 
+P≤0.05, ++P≤0.01; AP102 3 μg/kg/h: ^P≤0.05 514 
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Figure 4: Mean (± SEM) plasma IGF-1 levels measured before and following 1, 7, 14, 21, and 28 516 
days of chronic SC treatment with vehicle (sterile saline), pasireotide (3 or 10 μg/kg/h) or AP102 (3 or 517 
10 μg/kg/h) in male rats. Insets show mean (± SEM) area under the curve (AUC) for IGF-1 during the 518 
28-day treatment period. Symbols denote significant differences from vehicle treatment at individual 519 
time points: pasireotide 10 μg/kg/h: ***P≤0.001; pasireotide 3 μg/kg/h: +++P≤0.001; AP102 10 520 
μg/kg/h: °°°P≤0.001; AP102 3 μg/kg/h: ^^P≤0.01, ^^^P≤0.001  521 
 522 
Figure 5: Mean (± SEM) body weight (A) measured daily before and during 28-day chronic SC 523 
treatment with vehicle (sterile saline), pasireotide (3 or 10 μg/kg/h) or AP102 (3 or 10 μg/kg/h) in 524 
male rats.  Mean (± SEM) femur (B), nose-to-anus (C), and tail (D) length were measured following 525 
14 and/or 28 days of chronic treatment. Symbols denote significant differences from vehicle 526 
treatment: pasireotide 10 μg/kg/h: **P≤0.01; ***P≤0.001; pasireotide 3 μg/kg/h: +P≤0.05; ++P≤0.01; 527 
+++P≤0.001; AP102 10 μg/kg/h: °°P≤0.01; °°°P≤0.001 528 
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